Jefferies initiated coverage of ALX Oncology (ALXO) with a Buy rating and $4 price target ALX has strategically focused on two lead programs, Evorpacept in post-ENHERTU HER2+ mBC using prospective CD47 enrichment, supported by “encouraging” gastric data and ALX2004, an ADC with a differentiated design for wider therapeutic window in solid tumors, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO: